Form 4: EcoR1 Capital Increases Stake in Zymeworks Inc. Through Recent Share Purchases

EcoR1 Capital, a significant shareholder in Zymeworks Inc., has increased its holdings through recent purchases of common stock.

Summary

• EcoR1 Capital, along with Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P., has reported purchasing additional shares of Zymeworks Inc. common stock.
• On January 16, 2025, they acquired 121,681 shares at a price of $13.885 per share.
• Following this, on January 17, 2025, they purchased another 19,748 shares at $13.8747 per share.
• These transactions increased their total indirect beneficial ownership to 15,720,161 shares.
• The shares are held by private funds managed by EcoR1, with Oleg Nodelman as the controlling owner of EcoR1.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive as it reflects a continued investment by a major shareholder, which is generally seen as a positive sign. However, it is a routine filing and does not indicate any major change in the company's prospects.

Positives

• The increased share purchases by EcoR1 Capital indicate a continued investment and confidence in Zymeworks Inc.

Risks

• The document does not explicitly state any risks, but the concentration of ownership by EcoR1 Capital could potentially influence the company's direction.

Management Comments

• The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934.
• The filers disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein.

Industry Context

This filing reflects a significant investor's continued interest in Zymeworks, a biotechnology company. Such transactions are common in the biotech sector, where institutional investors often adjust their holdings based on company performance and market conditions.

Comparison to Industry Standards

• Similar filings are common for institutional investors in publicly traded biotech companies, such as those made by entities like Baker Bros. Advisors or RA Capital Management when they adjust their positions in companies like BioMarin or Vertex Pharmaceuticals.
• The size of the transaction is not unusual for a fund of EcoR1's size, and the price paid is consistent with the market price at the time of the transaction.

Stakeholder Impact

• The increased ownership by EcoR1 Capital could be viewed positively by shareholders, potentially increasing confidence in the company's future.

Key Dates

Keywords

Zymeworks Inc., EcoR1 Capital, Share Purchase, Beneficial Ownership, Oleg Nodelman, Stock Transaction, Investment